BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA a Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology. LONDON: BioMed Central, 2015, roč. 15, MAR 24 2015, s. "nestránkováno", 10 s. ISSN 1471-230X. Dostupné z: https://dx.doi.org/10.1186/s12876-015-0266-6. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1315243, author = {Bencsiková, Beatrix and Bortlíček, Zbyněk and Halámková, Jana and Ostrizkova, Lenka and Kiss, Igor and Melichar, Bohuslav and Pavlík, Tomáš and Dušek, Ladislav and Valík, Dalibor and Vyzula, Rostislav and Zdražilová Dubská, Lenka}, article_location = {LONDON}, article_number = {MAR 24 2015}, doi = {http://dx.doi.org/10.1186/s12876-015-0266-6}, keywords = {Colorectal cancer; Angiogenesis inhibitors; Bevacizumab; KRAS; Biomarkers; Antineoplastic agents; Clinical practice}, language = {eng}, issn = {1471-230X}, journal = {BMC Gastroenterology}, title = {Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view}, volume = {15}, year = {2015} }
TY - JOUR ID - 1315243 AU - Bencsiková, Beatrix - Bortlíček, Zbyněk - Halámková, Jana - Ostrizkova, Lenka - Kiss, Igor - Melichar, Bohuslav - Pavlík, Tomáš - Dušek, Ladislav - Valík, Dalibor - Vyzula, Rostislav - Zdražilová Dubská, Lenka PY - 2015 TI - Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view JF - BMC Gastroenterology VL - 15 IS - MAR 24 2015 SP - "nestránkováno" EP - "nestránkováno" PB - BioMed Central SN - 1471230X KW - Colorectal cancer KW - Angiogenesis inhibitors KW - Bevacizumab KW - KRAS KW - Biomarkers KW - Antineoplastic agents KW - Clinical practice N2 - Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients. ER -
BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA a Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. \textit{BMC Gastroenterology}. LONDON: BioMed Central, 2015, roč.~15, MAR 24 2015, s.~''nestránkováno'', 10 s. ISSN~1471-230X. Dostupné z: https://dx.doi.org/10.1186/s12876-015-0266-6.
|